Breast cancer: beyond the cutting edge. - Wikidata - awgldk - TriplyDB

Breast cancer: beyond the cutting edge.

Breast cancer: beyond the cutting edge.

http://www.wikidata.org/entity/Q37598890

about

Are there any differences between features of proteins expressed in malignant and benign breast cancers?Modeling, design and synthesis of new heteroaryl ethylenes active against the MCF-7 breast cancer cell-line.Characteristics of human Ewing/PNET sarcoma models.

P2860

Q34864350-31AE37EA-092B-4332-9567-0CE67212D6F8 Q34881760-942297FC-A7D1-4023-88BA-E08C15796426 Q35008659-A87DCD40-07CF-4864-B64A-2FC4A023842A

P2860

Breast cancer: beyond the cutting edge.

http://www.wikidata.org/entity/Q37598890

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Breast cancer: beyond the cutting edge.

@en

Breast cancer: beyond the cutting edge.

@nl

type

label

Breast cancer: beyond the cutting edge.

@en

Breast cancer: beyond the cutting edge.

@nl

prefLabel

Breast cancer: beyond the cutting edge.

@en

Breast cancer: beyond the cutting edge.

@nl

P1433

Q37598890-71E2E188-84CE-48DA-82E8-EAFFE55D99D2

P1476

Q37598890-AC7C8164-9D6F-44B7-9667-610D61DAD8EA

P2093

Q37598890-BD281690-8452-4873-A749-B9230BB19596

P2860

Q37598890-033CB33F-595A-4446-B8C6-3A0395E273CE

Q37598890-03BAD397-DC6C-436F-A1C6-E944E4B44073

Q37598890-04CDE979-C27A-4CC9-BB10-14E215AEF034

Q37598890-06C4FAE8-B582-4978-A73A-6CF4FADE5BE8

Q37598890-0928CE89-260E-4851-8625-89F8B7BB09DC

Q37598890-095F3ADE-FDF1-4431-8769-5816BE5157E6

Q37598890-0B6E3A20-2466-4ED5-B739-A375D2C2BD93

Q37598890-0F8816C9-0A4A-41CF-B319-995DE0CEF910

Q37598890-0FA82A92-0D23-4E00-9C32-005C9E536A40

Q37598890-104F524E-079C-4C7D-84EF-F03DEA98AAC4

P304

Q37598890-17B4A4A9-A899-4F81-A81E-7C892EBC3047

P31

Q37598890-42F7148C-EB72-40F6-8D87-72AF3ECD716A

P356

Q37598890-98B7BFAB-F400-468C-9EF2-D7596E1AE075

P407

Q37598890-EFAE617C-E311-4A2B-A2FA-C1B33E840E04

P433

Q37598890-98846A18-F2AF-4C79-8E14-A9508C027762

P478

Q37598890-A0B0A528-F805-4B8E-87C1-EF1BF21B5F59

P577

Q37598890-CF214F58-A41E-44DD-8CD3-A96985F8D51E

P698

Q37598890-0945CBFB-A70A-48C9-839C-F0D18BDFA0EE

P356

14656560903167957

P1433

Expert Opinion on Pharmacotherapy

P1476

Breast cancer: beyond the cutting edge.

@en

P2093

Gerald M Higa

http://www.w3.org/2001/XMLSchema#string

P2860

Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells

Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes

Genome-wide association study identifies novel breast cancer susceptibility loci

How many more breast cancer predisposition genes are there?

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Cancer statistics, 2008

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

P304

2479-2498

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656560903167957

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19761355

http://www.w3.org/2001/XMLSchema#string